文献速递骨软组织肉瘤与黑色素瘤

人工智能检测肿瘤浸润淋巴细胞与抗PD-1治疗黑色素瘤的结局

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项多中心队列研究纳入1202例晚期黑色素瘤患者,使用Hover-NeXt模型在治疗前HE染色转移灶中检测TIL百分比。TIL每增加10%,ORR的调整OR为1.40,PFS的调整HR为0.85,OS的调整HR为0.83,且AI检测TIL与疗效和生存的关联强于人工评分。

要点

  • AI检测治疗前HE染色转移灶TIL百分比,每增加10%与ORR提高、PFS和OS改善独立相关。
  • 该关联在抗PD-1单药和抗PD-1联合抗CTLA-4治疗患者中一致。
  • AI检测TIL与疗效和生存的关联强度优于按指南人工评分。

核心结论

  • 在晚期黑色素瘤患者中,治疗前HE切片上AI检测的TIL水平越高,ICI应答和生存结局越好,且为独立关联。

研究设计与样本

  • 多中心队列研究,纳入2016年1月至2023年1月荷兰11家黑色素瘤治疗中心接受一线抗PD-1±抗CTLA-4治疗的晚期黑色素瘤患者1202例。
  • 中位随访36.3个月(95%CI,34.0-39.1),数据分析时间为2025年1月至7月。

主要发现

  • 1202例患者中女性445例(37.0%),男性757例(63.0%),中位年龄67.0岁(IQR 57.0-74.0)。
  • TIL百分比中位数为9.9%(范围0.3%-69.4%)。
  • TIL每增加10%,ORR的调整OR为1.40(95%CI,1.23-1.59),PFS的调整HR为0.85(95%CI,0.79-0.92),OS的调整HR为0.83(95%CI,0.76-0.91)。
  • 423例接受联合治疗,结果在抗PD-1单药和联合治疗患者中一致。
  • AI检测TIL与疗效和生存的关联始终强于人工TIL评分。

临床怎么用

  • AI检测TIL可基于常规HE染色切片完成,有望作为ICI疗效的易获取生物标志物。
  • Hover-NeXt架构和模型权重已公开,便于外部验证和更广泛推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Easy and accessible biomarkers associated with response to immune checkpoint inhibition (ICI)-treated melanoma are limited. OBJECTIVE: To evaluate artificial intelligence (AI)-detected tumor-infiltrating lymphocytes (TILs) on pretreatment melanoma metastases as a biomarker for response and survival in patients treated with ICIs. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study included patients with advanced melanoma treated with first-line anti-programmed cell death 1 protein (PD-1) with or without anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) between January 2016 and January 2023 at 11 melanoma treatment centers in the Netherlands. Data were analyzed from January to July 2025. EXPOSURE: All patients received first-line anti-PD-1 with or without anti-CTLA-4. MAIN OUTCOMES AND MEASURES: The percentage of TILs inside manually annotated tumor area in hematoxylin-eosin-stained pretreatment metastases was determined using the Hover-NeXt model trained and evaluated on an independent melanoma dataset containing 161 835 pathologist-verified manually annotated cells. The primary outcome was objective response rate (ORR); secondary outcomes were progression-free survival (PFS) and overall survival (OS). Correlation with manual TILs, scored according to the guidelines stated by the Immuno-Oncology Biomarkers Working Group, was evaluated with Spearman correlation coefficients. Logistic regression and Cox proportional regression were conducted, adjusted for age, sex, disease stage, ICI type, BRAF status, brain metastases, lactate dehydrogenase level, and performance status. RESULTS: Of 1202 included patients with advanced cutaneous melanoma, 445 (37.0%) were female and 757 (63.0%) were male, and the median (IQR) age was 67.0 (57.0-74.0) years. The median follow-up was 36.3 months (95% CI, 34.0-39.1). Metastatic melanoma specimens were available for 1202 patients, of whom 423 received combination therapy. The median (range) TIL percentage was 9.9% (0.3%-69.4%). A 10% increase in TILs was associated with increased ORR (adjusted odds ratio, 1.40; 95% CI, 1.23-1.59), PFS (adjusted hazard ratio, 0.85; 95% CI, 0.79-0.92), and OS (adjusted hazard ratio, 0.83; 95% CI, 0.76-0.91). Results were consistent for both patients treated with anti-PD-1 monotherapy and patients treated with combination treatment with anti-PD-1 plus anti-CTLA-4. When comparing manual TIL scoring with AI-detected TILs, associations with response and survival were consistently stronger for AI-detected TILs. CONCLUSIONS AND RELEVANCE: In this cohort study, among patients with advanced melanoma, higher levels of AI-detected TILs on pretreatment hematoxylin-eosin slides were independently associated with improved ICI response and survival. Given the accessibility of TIL scoring on routine histology, TILs may serve as a biomarker for ICI outcomes. To facilitate broader validation, the Hover-NeXt architecture and model weights are publicly available.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Schuiveling M, van Duin IAJ, Ter Maat LS, et al. Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma. JAMA Oncol. 2025. PMID: 41100131. doi:10.1001/jamaoncol.2025.4072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。